You are here:Home-Inhibitors & Agonists-Cell Cycle/DNA Damage-ATM/ATR

Request The Product List ofATM/ATR ATM/ATR

Cat. No. Product Name CAS No. Information
PC-61826

AZD1390

2089288-03-7

AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM, displays >1,000-fold selectivity over closely related (PIKKs) and distant kinases; radiosensitises a panel of glioblastoma multiforme (GBM) cell lines and NCI-H2228 lung cells (IC50=3 nM); demonstrates potential in combination with radiation therapy for the treatment of brain tumors.

Brain Cancer

Phase 1 Clinical

PC-70146

BAY-1895344 hydrochloride

BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.

Blood Cancer

Phase 1 Clinical

PC-60277

BAY-1895344

1876467-74-1

BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.

Blood Cancer

Phase 1 Clinical

PC-44042

VE-821

1232410-49-9

A potent, selective and ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM; shows excellent selectivity for ATR over the related PIKKs ATM, DNA-PK, mTOR and PI3K.

PC-42030

AZD-0156

1821428-35-6

AZD-0156 (AZD0156, AZD 0156) is a potent, highly selective and orally bioavailable ATM inhibitor; exhibits antitumoral activity, both reducing tumor burden and preventing tumors from growing in an immunocompetent allograft mouse model of AML.

Solid Tumors

Phase 1 Clinical

PC-45607

AZD-6738

1352226-88-0

AZD-6738 (AZD6738, Ceralasertib) is a potent and selective inhibitor of ATR with IC50 of 1 nM; shows no significant activity for ATM, DNA-PK and mTOR; inhibits ATR kinase-dependent CHK1 phosphorylation in cells (IC50=74 nM); enhances the therapeutic efficacy of cisplatin in xenograft models; orally active and bioavailable.

Gastric Cancer

Phase 2 Clinical

PC-42778

CP-466722

1080622-86-1

A poten and selective ATM inhibitor without effect on ATR kinase; does not inhibit PI3K, PI3K-like protein kinases or Abl kinase and disrupts ATM-dependent cell cycle checkpoints in cells.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com